ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 929,30
-0,70%
Dow Jones
37 903,29
0,00%
DAX
17 940,91
0,11%
Brent Oil
84,21
0,80%
Bitcoin
58 516,20
0,48%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Theravance Biopharma Inc (TBPH)

  7. Theravance Biopharma Inc (TBPH) Actualités

TBPH Theravance Biopharma Inc

8,84
0,00 (0,00%)
Avant marché
Dernière mise à jour : 13:00:00
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Theravance Biopharma Inc TBPH NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 8,84 13:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
8,84
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
29/4/202412:00PRNUSTheravance Biopharma to Report First Quarter 2024 Financial..
10/4/202412:00PRNUSTheravance Biopharma, Inc. to Host Virtual Key Opinion..
26/2/202422:16EDGAR2Form 8-K - Current report
26/2/202422:05PRNUSTheravance Biopharma, Inc. Reports Fourth Quarter and Full..
23/2/202402:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202402:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202402:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202402:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202402:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202412:00PRNUSTheravance Biopharma to Participate in an Upcoming Investor..
17/2/202402:12EDGAR2Form 3 - Initial statement of beneficial ownership of..
14/2/202422:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
14/2/202412:00PRNUSTheravance Biopharma to Report Fourth Quarter and Full Year..
16/1/202412:16EDGAR2Form 8-K - Current report
05/1/202412:07EDGAR2Form 8-K - Current report
05/1/202412:00PRNUSTheravance Biopharma Announces Results from the Phase 4..
28/12/202312:01EDGAR2Form 8-K - Current report
27/12/202300:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/12/202300:06EDGAR2Form 3 - Initial statement of beneficial ownership of..
21/12/202323:10EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
21/12/202323:06EDGAR2Form 8-K - Current report
21/12/202323:00PRNUSTheravance Biopharma, Inc. Announces Appointment of Jeremy..
18/12/202312:00PRNUSTheravance Biopharma to Conduct Investor Meetings During the..
23/11/202300:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/11/202300:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/11/202300:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/11/202300:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202300:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/11/202312:00PRNUSTheravance Biopharma to Present New Ampreloxetine Data at..
15/11/202312:00PRNUSTheravance Biopharma to Participate in the 6th Annual..
13/11/202314:00PRNUSViatris and Theravance Biopharma Announce Positive Top-Line..
09/11/202322:46EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202322:53EDGAR2Form 8-K - Current report
07/11/202322:28PRNUSTheravance Biopharma, Inc. Reports Third Quarter 2023..
01/11/202323:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/10/202322:15EDGAR2Form 8-K - Current report
19/10/202312:00PRNUSTheravance Biopharma to Report Third Quarter 2023 Financial..
19/10/202300:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/10/202322:13EDGAR2Form 144 - Report of proposed sale of securities
19/9/202300:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/9/202322:24EDGAR2Form 144 - Report of proposed sale of securities
12/9/202312:05EDGAR2Form 8-K - Current report
29/8/202312:00PRNUSTheravance Biopharma to Participate in an Upcoming Investor..
28/8/202312:05PRNUSTheravance Biopharma to Present New Ampreloxetine Data at..
25/8/202300:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/8/202300:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/8/202300:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/8/202300:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/8/202300:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/8/202300:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Dernières Valeurs Consultées

NASDAQ
TBPH
Theravance Biopharma
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés